Rapid clinical improvement of refractory subacute cutaneous lupus erythematosus with oral tyrosine kinase 2 inhibitor deucravacitinib: A case report.

This article, published in the Journal of the European Academy of Dermatology & Venereology, presents a case report on the rapid clinical improvement of refractory subacute cutaneous lupus erythematosus (SCLE) with the use of the oral tyrosine kinase 2 inhibitor deucravacitinib. The report highlights the challenges in treating severe cases of cutaneous lupus erythematosus (CLE) and discusses the potential of januskinase inhibition as an alternative therapy. The case study describes a 56-year-old Vietnamese patient with SCLE who showed significant improvement in symptoms after starting deucravacitinib treatment. The authors suggest that further research is needed to explore the safety, effectiveness, and tolerability of deucravacitinib in managing patients with SCLE. [Extracted from the article]